Please login to the form below

Not currently logged in
Email:
Password:

IBS

This page shows the latest IBS news and features for those working in and with pharma, biotech and healthcare.

Merck buys cancer-killing virus firm Viralytics for $394m

Merck buys cancer-killing virus firm Viralytics for $394m

Trials of Cavatek with Keytruda are ongoing in melanoma, prostate, lung and bladder cancers, and the two companies have already reported phase Ib data showing that the duo achieved a 100%

Latest news

More from news
Approximately 6 fully matching, plus 88 partially matching documents found.

Latest Intelligence

  • Erectile dysfunction, constipation, vaginal dryness and other laughing matters Erectile dysfunction, constipation, vaginal dryness and other laughing matters

    An Irritable Bowel Syndrome campaign tackled the challenge of IBS not being taken seriously by actually using humour. ... However, FiberOne poked fun at doctors and their scepticism of the legitimacy of IBS.

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Data was presented from a Phase Ib study on Biogen’s aducanumab which showed statistically significant reductions in amyloid plaques in the brain compared with placebo among 31 early-stage ... Positive results from a phase Ib dose-escalation study were

  • Deal Watch January 2017 Deal Watch January 2017

    Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis (ABI-M201) and Crohn's disease plus 2 compounds for IBS.

  • Deal Watch January 2016 Deal Watch January 2016

    TEN-010, the lead, is a small molecule BET inhibitor that is in two phase Ib oncology studies. ... It is expected that $30m of payments will fall in 2016 relating to the phase Ib studies for SER 262 and a late stage study for SER 109 in CDI.

  • Pharma deals in February 2015 Pharma deals in February 2015

    diarrhoea (IBS-D) label be successful, this figure could rise to $2bn.

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics